List of Diagnostics Companies in New York - 48

Alpha-1 Biologics is a biotherapeutics company developing innovative treatments for cancers and immune deficiencies. The company is dedicated to their mission to develop patented therapeutics related to the generation of immune cells from stem cells within the body to treat immunodeficiency with disease applications including immune cell replenishment in cancer therapy, HIV/AIDS, patients with inherited deficiency of α1PI, and in the most prevalent cause of immune deficiency, malnutrition. Alpha-1 Biologics is currently testing their orally-available, small molecules in studies to determine their ability to increase the number of tumor infiltrating CD4+ T cells and coordinate with immune checkpoint inhibitors to eliminate tumors. The discoveries at the core of Alpha-1 Biologics therapeutic approach resulted from basic research conducted by Dr. Bristow and supported for many years by the non-profit research organization, Institute for Human Genetics and Biochemistry (IHGB) funded by the Harry Winston Research Foundation.

Revolutionizing Diabetes Care: No More Needles! At Apollon Inc., we're changing the game for diabetes management. Imagine checking your blood sugar without a single prick - that's what our new continuous glucose monitoring (CGM) system does. Using cutting-edge Raman spectroscopy, we're making glucose monitoring easy, painless, and affordable for everyone. Our device is as small as a smartwatch, needle-free, and designed with your safety in mind. We're currently working with MIT to perfect it, bringing together the best talent from Boston to Seoul. Diabetes affects millions worldwide, and we're here to make their lives better. Our goal? To help more people manage their health easily and comfortably. Join us in this exciting journey. Together, we can improve lives, one simple glucose check at a time. Let's make diabetes management stress-free for everyone!

Develops DNA Security Tags, Molecular diagnostics, and vaccines.COVID-19: Applied DNA and Takis Biotech completed the design of a diagnostic kit for SARS-COV-2 (the virus that causes the disease COVID-19) being developed for production via the company’s proprietary PCR-based DNA (LineaRx™) manufacturing process. They also work with Takis on vaccines. EUA (05/2020)

AptaMatrix is a privately held, start-up biotechnology company headquartered in Syracuse, New York. The company's focus is to accelerate the rate of aptamer discovery using its patent pending High Throughput Screening of Aptamers (HTSA) approach in addition to developing its novel AlloSwitch™ sensor technology capable of a) creating rapid diagnostic tools for detection of chemical and biological targets, and b) leveraging this diagnostic platform for drug discovery applications. AlloSwitches™, have demonstrated the ability to transduce molecular recognition of biological targets into a real-time (seconds) optical signal for identifying environmental and terrorist released contaminants in liquid systems. HTSA and AlloSwitch solutions are built on patented biotechnology based on years of leading-edge biological research and industry partnerships at Syracuse University. The HTSA approach leverages the high throughput capabilities of deep-sequencing technology. All sequencing activity is managed by our Genomics Division and conducted on our Illumina GAIIx platforms. Data analysis is supported by our in-house bioinformatics team. In addition to supporting internal research and development, our genomics division actively supports both academic and commercial deep-sequencing projects.

Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai.

AXIM Biotechnologies is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical, and cosmetic products as well as alternative energy sources. We prioritize the well-being of our customers while embracing a solid fiscal strategy. We believe in setting the green standard for cannabinoid bioscience through the discovery and commercialization of new materials and technologies for healthy living while respecting the environment. Public Relations Contact Andrew Hard Chief Executive Officer CMW Media andrew.hard@cmwmedia.com P. +1888 829-0070 www.cmwmedia.com Investor Relations Contact Shiwei Yin, Grayling Shiwei.Yin@grayling.com P. +1646 824-2857 Lucia Domville, Grayling lucia.domville@grayling.com P. +1646 284-9416

For over 30 years, Bionique Testing Laboratories has been a trusted partner and global leader of Mycoplasma Testing Services for the life science industry. Bionique offers the full breadth of GMP services from Lot & Final Drug Product Release Testing to Real-Time PCR assays. Our service portfolio and depth of expertise enables us to support our clients’ needs from concept through clinical trials to commercialization for biopharmaceutical and cell therapy products. Our capabilities extend to successful method development and validation inclusive of rapid microbiological methods to generate real time results. Bionique stands ready to provide the highest quality of mycoplasma testing services to ensure the integrity and biosafety of your therapeutic products. Mycoplasma Testing Solutions for: • Cell and Gene Therapy Products • Clinical Trial Materials • Biopharmaceuticals • Master and Working Cell Banks • Raw Materials • Vaccines Bionique is a cGMP compliant, FDA-registered facility.

For over 30 years, Bionique Testing Laboratories has been a trusted partner and global leader of Mycoplasma Testing Services for the life science industry. Bionique offers the full breadth of GMP services from Lot & Final Drug Product Release Testing to Real-Time PCR assays. Our service portfolio and depth of expertise enables us to support our clients' needs from concept through clinical trials to commercialization for biopharmaceutical and cell therapy products. Our capabilities extend to successful method development and validation inclusive of rapid microbiological methods to generate real time results. Bionique stands ready to provide the highest quality of mycoplasma testing services to ensure the integrity and biosafety of your therapeutic products. Mycoplasma Testing Solutions for: • Cell and Gene Therapy Products • Clinical Trial Materials • Biopharmaceuticals • Master and Working Cell Banks • Raw Materials • Vaccines Bionique is a cGMP compliant, FDA-registered facility.

For more than four decades, BioReference has built a legacy based on scientific excellence, innovation and world-class service in laboratory testing solutions. Amidst a tidal wave of change in healthcare in recent years, BioReference has evolved, adding significant services and solutions aimed at addressing the needs of today’s customers. Laboratory testing remains the cornerstone to the services we provide. As we challenge the limits of specialty diagnostics, we are making strategic investments to continue drive innovation and cultivate a unique customer experience, as well as expanding our reach to match the dynamic needs of an ever-changing healthcare system. BioReference offers scientific expertise and laboratory innovation in oncology, urology, and women’s health. Our organization provides credible and tailored solutions for a wide spectrum of customers and patients, including medical practices small and large, hospitals and health systems, correctional institutions, government agencies, educational systems, sport leagues, travel and leisure industries, and retail markets. In addition to an extensive test menu with 99% of tests performed in-house, BioReference’s differentiated offerings include large-scale health screening programs, on-demand mobile phlebotomy, and transformative business solutions that optimize laboratory testing and management. BioReference is part of OPKO Health, Inc., a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets. Headquartered in Elmwood Park, New Jersey, BioReference operates 10 laboratory facilities around the country, is in-network with the largest health plans in the United States, and serves over 19 million patients annually.

Biotia is a health tech company launched from Jacobs Technion-Cornell Institute at Cornell Tech in association with Weill Cornell Medicine, located in New York, NY, that leverages DNA sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Biotia is developing a next-generation sequencing-based test for COVID-19 that characterizes genetic variance across the whole viral genome.

About Chembio Diagnostics: Chembio is a leading point-of-care diagnostics company focused on creating fast actionable tests to diagnose diseases quickly and accurately, including STIs and COVID-19, enabling expedited treatment. Chembio tests are easy to use and provide results in approximately 15 minutes using some of the smallest sample sizes of fingertip blood, nasal swabs and other sample types. Chembio recently received FDA CLIA Waiver for the first rapid point-of-care combination test for HIV & Syphilis. Coupled with Chembio's extensive scientific expertise, its novel DPP® technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com. About the DPP Rapid Test Platform: Chembio's proprietary DPP® technology platform provides high-quality, rapid diagnostic results in 15 to 20 minutes using a small drop of blood from the fingertip or alternative samples. Through advanced multiplexing, the DPP platform can detect up to eight, distinct test results from a single patient sample, delivering greater clinical value than other rapid tests. For certain applications, Chembio's easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzer then reports accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on-site. Objective results produced by the DPP Micro Reader reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.

Chemeleon has created a platform technology for the rapid, instrument-free, detection of chemical compounds in the field, obviating the need for slow, complex, and expensive lab analysis. Our sensor materials combine highly selective molecular receptors with colorimetric nanomaterial reporters to provide an autonomous and inert means of optically detecting hazardous chemicals in virtually any environment, from clinical to third-world settings.

Creative Diagnostics is a biotechnology company based in Shirley, New York, specializing in diagnostic reagents and contract research services. Established in the early 2000s, the company serves global markets in biopharmaceuticals, diagnostics, and academic research. With a team of 25 to 200 employees, Creative Diagnostics generates an estimated annual revenue of $5 million to $25 million. The company offers a range of products, including research-grade and therapeutic antibodies, viral antigens for vaccine development, customizable ELISA kits, rapid test kits, and specialized reagents for gene therapy and bioanalysis. Creative Diagnostics also provides contract assay development, GMP manufacturing for biologics, and custom antibody development through its proprietary Omni-Hybridoma™ platform. Its technical capabilities support rapid commercialization and are particularly relevant for mRNA vaccine development and therapeutic drug monitoring.

For more than 45 years, Enzo Biochem has been a leader in innovation and product development to support a diverse range of needs in biomedical research and healthcare. With a comprehensive portfolio of 20,000 high-quality products including antibodies, genomic probes, assays, biochemicals, and proteins, Enzo supports the work of academic research centers and industry partners who are shaping the future of healthcare around the world. The company's proprietary products and technologies play central roles in all areas of translational research and drug development, including genomic analysis, protein analysis, cellular analysis, tissue analysis, and small molecule chemistry. Enzo Biochem has a broad and deep intellectual property port-folio, with patent coverage across a number of key enabling technologies.

We are on a mission to build a revolutionary cancer diagnosis platform to solve the challenge of early cancer prognosis and detection, as well as prediction of post-diagnosis cancer drug response.

Evvy is unlocking precision women's healthcare through novel, overlooked female biomarkers — starting with the vaginal microbiome. Backed by leading healthcare investors such as General Catalyst, Left Lane Capital, and LabCorp, the Evvy team includes leading OB/GYNs and vaginal microbiome researchers with decades of experience at organizations like UCSF, Stanford, Harvard, Cleveland Clinic, and more. Evvy is one of the fastest growing women's health companies in the US — enabling us to deliver innovative, high quality care while scaling novel R&D to unlock a new, data-driven future in women's health. Evvy's Vaginal Health Test is the first at-home vaginal microbiome test to use metagenomic sequencing to tell you what's up down there, why it matters, and what you can do about it. Evvy's larger platform is the first vaginal healthcare service to bring together state-of-the-art testing, precision clinical care, and 1:1 coaching to give women and people with vaginas the care they deserve. Through this platform, Evvy is building real-world datasets that can transform our understanding of complex female health conditions. Imagine a world where female health is finally understood: where risks are detected early and precisely; conditions are defined with specificity and nuance; and diseases are treated with personalization and care. That's the world that Evvy is pioneering.

Welcome to the future of neurological assessments with Firefly Neuroscience’s FDA-cleared Brain Network Analytics (BNA™). Utilizing ADVANCED AI and an extensive proprietary EEG database, BNA™ combines the automatic analysis of Event-Related Potentials (ERPs), spectral EEG, and behavioral performance data for a comprehensive and objective data-driven brain health evaluation.

Glycotest is Creating the New Clinical Standard for Early Diagnosis and Surveillance of Liver Cancer

HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both completing Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently in Phase 2 clinical development, modulates the anti-tumor innate immune response.

Isabl integrates the whole genome and transcriptome to inform cancer care

Proprietary applications in diagnostics and therapeutics. International technology development. Translational medicine impacting Immunology, Oncology and Genomics.

LetsGetChecked is a virtual care company that allows customers to manage their health from home, providing direct access to telehealth services, pharmacy, and laboratory tests with at-home sample collection kits for a wide range of health conditions including Sexual Health, Cholesterol, Diabetes, Thyroid, Coronavirus (COVID-19), and more. Founded in 2015, the company empowers people with the care they need to live longer, happier lives. Today, LetsGetChecked is a leader in healthcare innovation with an end-to-end model including manufacturing, logistics, lab analysis, affiliated physician support, and prescription fulfillment, which provides a seamless user experience and a convenient, reliable and secure healthcare experience. LetsGetChecked is available nationwide in the United States and most EU countries. It is co-headquartered in Dublin and New York, with teammates all over the world. To learn more visit www.letsgetchecked.com.

Linus Biotechnology is a patient-centric, breakthrough science, precision exposome medicine company. Our program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology.

Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. The phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. The lead compound LB-100 is in Phase I trial and has the potential to be first-in-class. The deacetylase inhibitors have anti-cancer activity and in model systems correct enzymes deficiencies underlying several inborn metabolic diseases including Gaucher and von Hippel-Lindau disease and neurofibromatosis type 2. Lixte's cancer drug development strategy has led to the discovery of novel compounds with the potential to be therapeutically useful against several other important but seemingly disparate diseases. The phosphatase inhibitors are in pre-clinical development for reducing the extent of tissue damage following stroke, heart attack, and septic shock; and, the deacetylase inhibitors for prevention and treatment of neurodegenerative diseases, traumatic brain injury, and topically for fungal dermatitis .

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device. EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device designation and is the subject of two large, actively enrolling, international multicenter clinical trials to support FDA PMA approval. Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing.

Matter Bio is a longevity holding company focused on preserving genome integrity As we age, our genome is constantly being damaged by exogenous and endogenous sources. Occasionally errors are missed and incorporated into the DNA in the form of mutations, structural variations, epigenetic drift, and other types of information loss. At Matter, we have assembled a world-class team of scientists and executives to help counter this critical information loss in the genome. To achieve this, we are focusing on a number of assets that address key stages in the genomic information loss continuum.

Focus on women's heatlh

Diagnostics We build innovative diagnostic and monitoring tools that empower people to make better decisions about their health. Drug Discovery We translate early-stage research into customized RNAi and CRISPR Cas9 animal and cell models to accelerate drug development. Therapeutics We identify and validate new drug targets, unleashing the commercial potential of RNAi to benefit people on a global scale. Established in 2010 to harness the power of RNAi and genetic engineering technologies developed by our founders in the labs of the world's leading experts at Cold Spring Harbor Laboratory, Howard Hughes Medical Institute, and Harvard Medical School, Mirimus creates innovative research and clinical technologies to address health issues on a global scale. Today, Mirimus markets multiple unique and high-value drug discovery and diagnostic products and services, and is advancing a pipeline of therapeutic candidates in partnership with leading biopharma companies to create novel high-impact health care solutions that benefits society on a global scale. Mirimus' ability to leverage its cutting-edge science and proprietary technology platforms to rapidly create new, affordable technology and products at scale is core to the way we work. We embrace diversity and creativity and have a proven track record of innovative problem solving—which led to our recognition as a $1M grand prize winner of the XPRIZE competition by developing a radically affordable, rapid, non-invasive methodology for mass COVID-19 testing—driving us to make better drugs and detect disease earlier. At Mirimus, our ingenuity, respect for our colleagues' ideas and creativity, executional agility, and a commitment to global health equity combine to create a unique culture of innovation that delivers measurable progress.

Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner. We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

PAVmed (NASDAQ: PAVM) is a highly-differentiated, multi-product medical device company employing a unique and proven business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This model enables us to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation.

PLD is a leading supplier of over-the-counter solid and liquid dose remedies in the Analgesic, Cough/Cold, Allergy, Sleep/Awake/Motion, Digestive, Nutritional, First Aid, Electrolyte and Epsom Salt categories. We pride ourselves on delivering the highest quality product in the most cost-efficient manner possible. This includes adhering to cGMP and stringent FDA regulations, so every product we manufacture meets and even exceeds the industry's rigorous standards. Since we began in 1988, it is our unwavering commitment to excellence that has enabled us to grow to serve every major retailer in the U.S. and many around the globe. Today we remain at the forefront of the consumer healthcare industry with 1,000+ dedicated employees and more than 1,000,000 sq. ft. of state-of-the-art facilities across New York, California, Florida and South Carolina. Our Mission To provide high quality and affordable healthcare products that help people feel well through services that cultivate trust and confidence. We foster an environment where people are passionate about their work and the wellbeing of their communities. Our Vision To be the most respected, efficient, and reliable partner delivering healthcare products and services that improve People's Lives Daily. Interested in a career at PLD? Please visit: http://www.pldevelopments.com/careers/

PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis. Combining AI with our patented Morphology Feature Array® (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.

Prime Discoveries develops rapid, novel diagnostics for emerging pathogen infections with a focus on cost effective, massively scalable and easily automatable assays. Prime leverages multiple patented advanced technologies in microbial diagnostics including RT-LAMP, Rapid PCR, and mNGS (Next generation sequencing) to enable samples to result in under 1 hour with minimal lab infrastructure and technical expertise. Prime's products are best in class for Covid, Influenza, Sexually Transmitted Infections and new drug resistant microbes. All of Prime's assays are locally developed in the United States and can serve millions of people. Founded in NYC in 2017, Prime's scientists have extensive backgrounds in microbiology, computational biology, lab automation and AI from Genentech, Cooper Genomics, Recombine, Phosphorus, and NYU. Prime is advised by leading experts in the fields of genomics and public health including Dr. George Church and Esther Dyson. Prime is supported by academic institutions, venture capital firms and angel investors including New York University, Charles Zegar, BoxGroup, Akron Fusion Ventures, Beresford Ventures, Cannonball Capital, Liquid 2 Ventures, Francois Nader (Moderna, Acceleron, Shire), Unshackled Ventures, Doberman Forward, and others.

ProPhase Labs Inc. (Nasdaq: PRPH) ("ProPhase") is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We're revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach.

Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary advancements in the early detection of autism spectrum disorder, Parkinson's disease, and mTBI, through the application of the Clarifi® epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. In March 2020, we made the decision to pivot and allocate some of our resources to directly address the pandemic. By leveraging our expertise in RNA analysis, we have been able to be part of three exciting COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S. In September 2020, The Clarifi COVID-19 Test Kit obtained Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) to be used for the diagnosis fo SARS-CoV-2.

A healthcare software company developing artificial intelligence (AI)-powered solutions, RADLogics provides machine learning image analysis solutions to improve radiologists' productivity while enhancing patient outcomes. Based in New York, NY, US, and Tel Aviv, Israel, RADLogics is one of the pioneers in using AI & machine learning image analysis and advanced big data analytics to search and analyze imaging data from CTs, MRIs, PET scans, and X-rays to help reduce diagnostics turnaround time from hours to minutes by automating detection and report generation functions. The company's patented AI medical image analysis platform enables rapid development of AI algorithms, and provides seamless integration into existing radiology workflow.

Rarecells develops and commercializes the ISET technology to isolate Circulating Cancer Cells for early cancer diagnosis and medical research. Rarecells® Diagnostics was created in 2010 by Patrizia Paterlini Brechot, Professor of Cell Biology and Oncology, in order to make the scientific and technological advances developed by her team available to research teams and patients. Rarecells® Diagnostics’ core product is the patented ISET® (Isolation by SizE of Tumor cells) Technology. Rarecells® Diagnostics has the exclusive license of patents belonging to the French Public Institutions University Paris Descartes, Assistance Publique Hôpitaux de Paris and INSERM protecting the Rarecells® Device and its consumables, as well as the analyses performed on cells isolated using the Rarecells® System. Rarecells® Diagnostics is a science-driven company. We are scientists working for scientists and patients. We care about bringing benefits to the patients.The team delivers customer satisfaction by manufacturing high quality products and providing high-level scientific assistance. Rarecells® and ISET® are registered trademarks of Rarecells SAS.

Renalytix is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease.COVID-19: Renalytix has entered into a joint venture with the Icahn School of Medicine at Mount Sinai (“Mount Sinai”), Kantaro Biosciences, LLC (“Kantaro”), to develop and scale production of COVID-19 antibody test kits.

Microfluidics for Molecular DiagnosticsCOVID-19: (12/2020) EUA for COVID-19™ MDx Assay

Rumi Scientific is a research-driven company focused on the discovery of drugs and innovative treatments for human genetic diseases. The company's mission is to fast-track the early stage of drug discovery using predictive models of the human brain for therapeutic success.

SandboxAQ is harnessing the exponential power of AI + Quantum (AQ) technology. The inspiration for SandboxAQ and some of the team originated at Alphabet Inc., becoming an independent entity in 2022. Our mission is to develop commercial products for financial services, healthcare, telecommunications, public sector, and other computationally-intensive industries. Our team's unique approach enables cross-pollination across a diverse range of fields, from physics, computer science, neuroscience, mathematics, cryptography, natural sciences, and more! Our success comes from coalescing diverse talent to create an environment where experimental thinking and collaboration yield breakthrough physics + AI solutions. Join a culture where thought leadership, diverse talent, employee engagement, and technological impact will create the next tech uproar. We are deeply committed to education as a means to advance quantum solutions and computing initiatives. We invest in future talent through internship programs, research papers, developer tools, textbooks, educational talks/events, and partnerships with universities/talent hubs to attract multi-disciplinary talent. Our hope is to inspire people from all walks of life to be prepared for the quantum era and encourage a path in STEM.

Summit Biomedical Imaging, LLC., a spin-off company from Memorial Sloan Kettering Cancer Center (MSK, New York City), was founded by Thomas Reiner and Christian Brand in 2016. Recently, Summit Biomedical Imaging was awarded a federal grant through NIH's Small Business Innovation Research (SBIR) program, also known as America's Seed Fund, to support the strong potential of commercialization of their innovative biomedical technology. This early-stage funding from the National Cancer Institute (NCI) allowed them to open their Research and Development facilities in the heart of New York City to develop novel targeted cancer diagnostics.

Sunrise Medical Laboratories. We put people first. For over 40 years, we at Sunrise Medical Laboratories have consistently provided our member physicians and their patients with the most accurate and diagnostically meaningful results possible. Our success stems from our commitment to three essential principles. Courtesy Whether you're a physician or a patient, your needs are our top priority. We are committed to providing prompt service, timely notice of appointments and results, and empowering our employees with the answers to any questions you may have. Compassion We know that medical testing can sometimes be worrisome or stressful. For this reason, we train our staff to provide information, care and comfort whenever needed. Whether it's distracting a child during a blood draw or explaining a complex test, we're glad to go the extra mile for each and every patient. Professional Expertise We continually invest in the most advanced technologies so that we can provide the highest quality medical laboratory services available. We are fully licensed and accredited by The College of American Pathologists (CAP), New York State Department of Health, the Center for Medicare and Medicaid Services (CLIA), U.S. Department of Health and Human Services (Medicare), and the Pennsylvania Department of Health. Because your well-being, comfort and peace-of-mind are utmost to our success, we are proud to say, "We take it personally".

At TRACER we are specialized in first-in-human studies with the use of nuclear and optical molecular imaging techniques. By labeling an antibody, small molecule, peptide, nanoparticle, protein, or any other compound of interest with a fluorescent dye or a radionuclide, fast in human data can be obtained with an indication of the potential efficacy of the novel drug, even before the classical phase 1-3 clinical trials. This can lead to a more efficient and less costly drug development process. We assist our sponsors in the labeling of their lead compounds and execute first-in-human studies to visualize and quantify the biodistribution and pharmacokinetics of the compound. With this information a “ go/no-go” decision can be made before the compound proceeds to the next phase in clinical development where costs are larger and time is valuable. Early in-human studies are approved by the EMA and FDA through the so-called principle of microdosing. It allows you to often skip (large) animal models and go straight into the patient population.

Triad Isotopes is a manufacturer and supplier of radiopharmaceutical products.

United Biomedical, Inc (UBI) is a privately held multinational biopharmaceutical company dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases. Our product pipeline is filled with our new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s Disease, AIDS, and Allergy, along with a portfolio of animal health diseases. These products are based on our proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies. Our platform technologies are also being used to develop a line of biosimilar versions of widely used protein and antibody drugs whose patents are about to expire. UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialized synthetic peptide vaccine. Additional revenue streams are generated from pharmaceutical contract manufacturing by our subsidiary UBI-Asia and various sponsorships in product development.

Headquartered in Rochester, NY, VisualDx’s team of physicians, educators, and computer scientists have developed an award-winning web-based clinical decision support system to enhance clinical decision-making and improve patient care. It has become the tool of choice for front line health care workers who are looking for a visual, curated, peer-reviewed approach to medicine.

ZeptoMetrix, an antylia scientific company, brings together some of the world's leading scientists in the fight against infectious disease. We are proud to offer an extensive range of research products and services that are continuously expanding. Our Mission "Partner to our Customer" is the basis for our successful collaboration with scientists across the globe.